This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buyon, J. Articles by Copel, J. Search for Related Content PubMed Articles by Buyon, J. Articles by Copel, J. Social Bookmarking                   What's this?

In Utero identification and therapy of congenital heart block

Department of Rheumatic Diseases, Hospital for Joint Diseases, 301 East 17th Street, New York University School of Medicine, New York, NY 10003

J. Waltuck

Department of Rheumatology, The Emory Clinic, 1365 Clifton Road NE Atlanta, GA 30322

C. Kleinman

Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510, USA

J. Copel

Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510, USA

To determine the feasibility and effectiveness of prenatal therapy of congenital heart block (CHB), information was sought regarding the timing of identification of CHB in 72 pregnancies and the outcome of those pregnancies in which the mothers were administered corticosteroids. Mailed questionnaires with telephone follow-up, data from primary physicians and chart review were utilized. In 38 (53%) of affected pregnancies CHB was identified between 16 and 24 weeks of gestation, in 17 (24%) between 25 and 30 weeks of gestation, in 8 (11%) between 31 and 37 weeks, and in 5 (7%) between 38 and 40 weeks. In four pregnancies the timing was unknown. Five women were taking prednisone for disease activity prior to the discovery of CHB and in six other women prednisone therapy was initiated at or about the time CHB was identified. In 19 pregnancies, women were given fluorinated steroids (available to the fetus in an active form) as attempted therapy after the discovery of CHB. Of these, one fetus with second degree block reverted to sinus rhythm and two with third degree block exhibited an improvement in the degree of block. In eight fetuses pleural and/or pericardial effusions resolved. In conclusion, the gestational period of heightened fetal vulnerability for the development of heart block is in the mid second to early third trimester. Although there is no evidence that maternal prednisone should be used prophylactially, fluorinated steroids may be efficacious after the identification of heart block, particularly with regard to an associated myocarditis.

Key Words: Neonatal lupus • congenital heart block • dexamethasone

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J.P. Buyon and R.M. Clancy Dying right to live longer: positing apoptosis as a link between maternal autoantibodies and congenital heart block Lupus, February 1, 2008; 17(2): 86 - 90. [Abstract] [PDF]

				A Tincani, D Bompane, E Danieli, and A Doria Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome) Lupus, March 1, 2006; 15(3): 156 - 160. [Abstract] [PDF]

				G.-Q. XIAO, Y. QU, K. HU, and M. BOUTJDIR Down-regulation of L-type calcium channel in pups born to 52 kDa SSA/Ro immunized rabbits FASEB J, July 1, 2001; 15(9): 1539 - 1545. [Abstract] [Full Text] [PDF]

				G.-Q. Xiao, K. Hu, and M. Boutjdir Direct Inhibition of Expressed Cardiac L- and T-Type Calcium Channels by IgG From Mothers Whose Children Have Congenital Heart Block Circulation, March 20, 2001; 103(11): 1599 - 1604. [Abstract] [Full Text] [PDF]

				M. Eronen, M.-K. Sirèn, H. Ekblad, T. Tikanoja, H. Julkunen, and T. Paavilainen Short- and Long-Term Outcome of Children With Congenital Complete Heart Block Diagnosed In Utero or as a Newborn Pediatrics, July 1, 2000; 106(1): 86 - 91. [Abstract] [Full Text]

				G Herrero-Beaumont, O Sánchez-Pernaute, and J C Acebes Pulmonary infiltrates and abdominal colic pain in a patient with a connective tissue disorder Ann Rheum Dis, January 1, 2000; 59(1): 15 - 19. [Full Text]

				K. SHINOHARA, S. MIYAGAWA, T. FUJITA, T. AONO, and K.-I. KIDOGUCHI Neonatal Lupus Erythematosus: Results of Maternal Corticosteroid Therapy Obstet. Gynecol., June 1, 1999; 93(6): 952 - 957. [Abstract] [Full Text] [PDF]

				J. A. Mazel, N. El-Sherif, J. Buyon, and M. Boutjdir Electrocardiographic Abnormalities in a Murine Model Injected With IgG From Mothers of Children With Congenital Heart Block Circulation, April 13, 1999; 99(14): 1914 - 1918. [Abstract] [Full Text] [PDF]

				M. E. Miranda, C.-E Tseng, W. Rashbaum, R. L. Ochs, C. A. Casiano, F. Di Donato, E. K. L. Chan, and J. P. Buyon Accessibility of SSA/Ro and SSB/La Antigens to Maternal Autoantibodies in Apoptotic Human Fetal Cardiac Myocytes J. Immunol., November 1, 1998; 161(9): 5061 - 5069. [Abstract] [Full Text] [PDF]